Board of directors of J. B. Chemicals & Pharmaceuticals Limited at its meeting held on February 5, 2026 has inter-alia approved: the appointment of Mr. Kaushal Solanki as the Chief Financial Officer of the Company with effect from February 5, 2026. Mr. Kaushal Solanki is a Chartered Accountant with over 30 years of experience in finance and had been associated with Torrent Pharmaceuticals Limited since October 2003. He has held several senior leadership roles in Torrent Pharmaceuticals Limited across financial reporting, internal audit, tax, international business finance, plant finance, and R&D finance, and has been closely involved in M&A evaluations.
J.B. Chemicals & Pharmaceuticals Limited is an India-based pharmaceutical company. The Company specializes in gastroenterology, hypertension and dermatology. It is also focused on other therapeutic categories like nephrology, respiratory, virology, diabetes, and nicotine replacement therapy (NRT). The Company is engaged in the business of manufacturing and marketing of diverse range of pharmaceutical formulations, herbal remedies and active pharmaceutical ingredients (APIs). Its brands include Nicardia, Cilacar, Rantac, Metrogyl, and Cilacar-T. It specializes in manufacturing of medicated and herbal lozenges. All its lozenges (herbal, medicated and soft-centered) can be made in sugar and sugar-free options. It has implemented osmotic-controlled release oral drug delivery system (OROS) technology. It maintains a direct presence in Russia and South Africa, along with distributor relationships in the United States and various markets throughout Asia, Africa, and Latin America.
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
